Paradoxically, upregulating PD-L1 expression (associated with immune suppression) in tumors that do not express it, creates a targetable immune-suppressive mechanism, allowing anti-PD-L1 therapy to re-activate anti-tumor T cells. Here, CD274 is linked to neoplasm.